Estimates of the Public Health Impact of a Pediatric Vaccination Program Using an Intranasal Tetravalent Live-Attenuated Influenza Vaccine in Belgium

被引:5
作者
Gerlier, Laetitia [1 ]
Lamotte, Mark [1 ]
Mendes, Sofia Dos Santos [2 ]
Damm, Oliver [3 ]
Schwehm, Markus [4 ]
Eichner, Martin [5 ,6 ]
机构
[1] IMS Hlth Real World Evidence Solut, Davos Bldg,Vincilaan 7, B-1935 Zaventem, Belgium
[2] SA AstraZeneca NV, Uccle, Belgium
[3] Univ Bielefeld, Bielefeld, Germany
[4] ExploSYS GmbH, Leinfelden Echterdingen, Germany
[5] Univ Tubingen, Inst Clin Epidemiol & Appl Biometry, Tubingen, Germany
[6] Epimos GmbH, Dusslingen, Germany
关键词
COST-EFFECTIVENESS; YOUNG-CHILDREN; ECONOMIC BURDEN; UNITED-STATES; EFFICACY; ENGLAND; GERMANY; FRANCE; TIME; METAANALYSIS;
D O I
10.1007/s40272-016-0180-6
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objectives Our objectives were to estimate the public health outcomes of vaccinating Belgian children using an intranasal tetravalent live-attenuated influenza vaccine (QLAIV) combined with current coverage of high-risk/elderly individuals using the trivalent inactivated vaccine. Methods We used a deterministic, age-structured, dynamic model to simulate seasonal influenza transmission in the Belgian population under the current coverage or after extending vaccination with QLAIV to healthy children aged 2-17 years. Differential equations describe demographic changes, exposure to infectious individuals, infection recovery, and immunity dynamics. The basic reproduction number (R-0) was calibrated to the observed number of influenza doctor visits/year. Vaccine efficacy was 80 % (live-attenuated) and 59-68 % (inactivated). The 10-year incidence of symptomatic influenza was calculated with different coverage scenarios (add-on to current coverage). Results Model calibration yielded R-0 = 1.1. QLAIV coverage of 75 % of those aged 2-17 years averted 374,000 symptomatic cases/year (57 % of the current number), 244,000 of which were among adults (indirect effect). Vaccinating 75 % of those aged 2-11 years and 50 % of those aged 12-17 years averted 333,200 cases/year (213,000 adult cases/year). Vaccinating only healthy children aged 2-5 years generated direct protection but limited indirect protection, even with 90 % coverage (40,800 averted adult cases/year; -8.4 %). Targeting all children averted twice as many high-risk cases as targeting high-risk children only (8485 vs. 4965/year with 75 % coverage). Sensitivity analyses showed the robustness of results. Conclusions The model highlights the direct and indirect protection benefits when vaccinating healthy children with QLAIV in Belgium. Policies targeting only high-risk individuals or the youngest provide limited herd protection, as school-age children are important influenza vectors in the community.
引用
收藏
页码:303 / 318
页数:16
相关论文
共 24 条
  • [1] Assessment of Public Health and Economic Impact of Intranasal Live-Attenuated Influenza Vaccination of Children in France Using a Dynamic Transmission Model
    Gerlier, L.
    Lamotte, M.
    Greneche, S.
    Lenne, X.
    Carrat, F.
    Weil-Olivier, C.
    Damm, O.
    Schwehm, M.
    Eichner, M.
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2017, 15 (02) : 261 - 276
  • [2] Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany
    Damm, Oliver
    Eichner, Martin
    Rose, Markus Andreas
    Knuf, Markus
    Wutzler, Peter
    Liese, Johannes Guenter
    Krueger, Hagen
    Greiner, Wolfgang
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2015, 16 (05) : 471 - 488
  • [3] The epidemiological impact of childhood influenza vaccination using live-attenuated influenza vaccine (LAIV) in Germany: predictions of a simulation study
    Rose, Markus A.
    Damm, Oliver
    Greiner, Wolfgang
    Knuf, Markus
    Wutzler, Peter
    Liese, Johannes G.
    Krueger, Hagen
    Wahn, Ulrich
    Schaberg, Tom
    Schwehm, Markus
    Kochmann, Thomas F.
    Eichner, Martin
    BMC INFECTIOUS DISEASES, 2014, 14
  • [4] Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany
    Oliver Damm
    Martin Eichner
    Markus Andreas Rose
    Markus Knuf
    Peter Wutzler
    Johannes Günter Liese
    Hagen Krüger
    Wolfgang Greiner
    The European Journal of Health Economics, 2015, 16 : 471 - 488
  • [5] Cost-Effectiveness of Intranasal Live-Attenuated Influenza Vaccine for Children: A Systematic Review
    Chan, Kenneth Sik-Kwan
    Wong, Charlene Hoi-Lam
    Choi, Horace Cheuk-Wai
    VACCINES, 2022, 10 (09)
  • [6] The epidemiological impact of childhood influenza vaccination using live-attenuated influenza vaccine (LAIV) in Germany: predictions of a simulation study
    Markus A Rose
    Oliver Damm
    Wolfgang Greiner
    Markus Knuf
    Peter Wutzler
    Johannes G Liese
    Hagen Krüger
    Ulrich Wahn
    Tom Schaberg
    Markus Schwehm
    Thomas F Kochmann
    Martin Eichner
    BMC Infectious Diseases, 14
  • [8] Development of a live-attenuated influenza B ΔNS1 intranasal vaccine candidate
    Wressnigg, Nina
    Voss, Daniel
    Wolff, Thorsten
    Romanova, Julia
    Ruthsatz, Tanja
    Mayerhofer, Ines
    Reiter, Manfred
    Nakowitsch, Sabine
    Humer, Johannes
    Morokutti, Alexander
    Muster, Thomas
    Egorov, Andrej
    Kittel, Christian
    VACCINE, 2009, 27 (21) : 2851 - 2857
  • [9] Impact of Pre-Existing Immunity to Influenza on Live-Attenuated Influenza Vaccine (LAIV) Immunogenicity
    Roy, Sreeja
    Williams, Clare M.
    Wijesundara, Danushka K.
    Furuya, Yoichi
    VACCINES, 2020, 8 (04)
  • [10] Influenza Vaccination with a Live Attenuated Vaccine The role of the pediatric nurse in immunization compliance
    Michael, Michele
    Helm, Elizabeth
    Van Graafeiland, Brigit
    Malinoski, Frank
    Bauman, Jay
    AMERICAN JOURNAL OF NURSING, 2009, 109 (10) : 44 - 48